AstraZeneca

As a company with more than 89,000 employees and $54 billion in revenue, AstraZeneca’s R&D team is a world leader in bringing new lifesaving innovations to the market. In 2021, the AstraZeneca team began developing a new first-in-class therapeutic candidate for the treatment of opioid use disorders (OUDs), and they recognized that a partnership with the NIH would be instrumental in catalyzing the successful product development and launch. However, AstraZeneca was not familiar with the NIH cooperative agreement funding opportunity that supports the development of novel medications for the treatment of OUDs. Therefore, AstraZeneca reached out to Eva Garland Consulting (EGC) for assistance in preparing an NIH proposal. 

To support AstraZeneca under a tight timeline, EGC assembled a team of Scientific Grants Experts who possess relevant scientific backgrounds in substance abuse disorder and drug development research, as well as experience with the targeted NIH grant mechanism. Within a span of 8 weeks, EGC’s and AstraZeneca’s teams collaborated to complete an NIH application. A few months later, the NIH indicated they intended to fund the award, and EGC supported AstraZeneca’s pre-award negotiations. The application was successful and resulted in a 4-year award of $11 million.

Over the years, AstraZeneca has also received over $1 billion in more than 20 government contracts from DoW, NIH, and VA, to manufacture COVID therapeutics, vaccines, medical supplies, etc.